(Albany, United States) As per DelveInsight’s assessment, globally, the Spinal Cord Injury Pipeline constitutes 35+ key companies continuously working towards developing 35+ Spinal Cord Injury Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Spinal Cord Injury Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Spinal Cord Injury NDA approvals (if any), and product development activities comprising the technology, Spinal Cord Injury collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Spinal Cord Injury Pipeline treatment landscape of the report, click here @ Spinal Cord Injury Pipeline Outlook

 

Key Takeaways from the Spinal Cord Injury Pipeline Report

• DelveInsight’s Spinal Cord Injury Pipeline analysis depicts a robust space with 35+ active players working to develop 35+ pipeline treatment therapies.
• The leading companies working in the Spinal Cord Injury Market include Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
• Promising Spinal Cord Injury Pipeline Therapies in the various stages of development include KAI-1678, Tadalafil, FAB117-HC, NVG-291, MT-3921, ALMB-0166, NeuroAiD, KP-100IT, Elezanumab, and others.
• On March 2023, Neuroplast announced a study of phase 1 clinical trials for Neuro-Cells. This phase I clinical study is an open clinical trial to investigate the safety of the intrathecal application of Neuro-Cells in the treatment of end stage (chronic), traumatic complete (AIS grade A) and incomplete (AIS grade B/C) SCI patients. To that purpose, after inclusion in this study >1 year and less than 5 years after their SCI-event, 10 patients will be included.
• On August 2023, NervGen Pharma announced a study of phase 1 & 2 clinical trials for NVG-291. To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments.

 

Spinal Cord Injury Overview

Spinal Cord Injury (SCI) is a condition in which damage to any part of the spinal cord or nerves at the end of the spinal canal (cauda equina) occurs. Spinal Cord Injury can be traumatic or non-traumatic.

 

For further information, refer to the detailed Spinal Cord Injury Unmet Needs, click here for Spinal Cord Injury Ongoing Clinical Trial Analysis

 

Spinal Cord Injury Emerging Drugs Profile

• ES 135: Eusol Biotech
• MT-3921: Mitsubishi Tanabe Pharma Corporation

 

Spinal Cord Injury Pipeline Therapeutics Assessment

There are approx. 35+ key companies which are developing the therapies for Spinal Cord Injury. The companies which have their Spinal Cord Injury drug candidates in the most advanced stage, i.e. Phase III include, Eusol Biotech.

 

Request a sample and discover the recent advances in Spinal Cord Injury Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Spinal Cord Injury Segmentation

 

Spinal Cord Injury Drugs and Companies

• KAI-1678: KAI Pharmaceuticals
• Tadalafil: Eli Lilly and Company
• FAB117-HC: Ferrer International S.A.
• NVG-291: NervGen Pharma

 

Spinal Cord Injury Therapeutics Assessment

• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Spinal Cord Injury Therapeutics Market include-

Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.

 

Dive deep into rich insights for drugs for the Spinal Cord Injury Pipeline, Click here @ Spinal Cord Injury Unmet Needs and Analyst Views

 

Scope of the Spinal Cord Injury Pipeline Report

• Coverage- Global
• Companies- Kringle Pharma, Eusol Biotech, Pharmicell, Pharmazz, AbbVie, Acorda Therapeutics, Geron Corporation, ReNetX Bio, GNT Pharma, AlaMab Therapeutics, Mitsubishi Tanabe Pharma, Kancera, Olatec Therapeutics, Scholar Rock, AXONIS Therapeutics, K-STEMCELL, Nordic Life Science Pipeline, NervGen Pharma, Athersys, Healios, Angiocrine Bioscience, and others.
• Therapies- KAI-1678, Tadalafil, FAB117-HC, NVG-291, MT-3921, ALMB-0166, NeuroAiD, KP-100IT, Elezanumab, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Spinal Cord Injury Merger and acquisitions, Licensing Activities

 

Table of Content

1. Introduction
2. Executive Summary
3. Spinal Cord Injury: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Spinal Cord Injury – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. ES 135: Eusol Biotech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. MT-3921: Mitsubishi Tanabe Pharma Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. NVG 291: NervGen Pharma
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. KAND-567: Kancera
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Spinal Cord Injury Key Companies
21. Spinal Cord Injury Key Products
22. Spinal Cord Injury- Unmet Needs
23. Spinal Cord Injury- Market Drivers and Barriers
24. Spinal Cord Injury- Future Perspectives and Conclusion
25. Spinal Cord Injury Analyst Views
26. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services